HUTCHMED (China) Limited (HK:0013) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HUTCHMED (China) Limited has appointed Cavendish Capital Markets Limited as a joint corporate broker in London, effective January 1, 2025. This move, alongside continuing partnerships with Panmure Liberum Limited and HSBC Bank plc, reflects HUTCHMED’s strategic efforts to strengthen its financial market presence. The biopharmaceutical company focuses on developing and commercializing therapies for cancer and immunological diseases.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
